{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:09:17Z","timestamp":1780520957114,"version":"3.54.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024390","name":"National Institute of Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024390","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijbiomac.2026.152557","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:57:29Z","timestamp":1778889449000},"page":"152557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Globotriaosylceramide (Gb3) implications in cardiovascular disease for its mechanistic insights, food chemistry aspects and clinical significance \u2014 A review"],"prefix":"10.1016","volume":"367","author":[{"given":"Vaishali","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Sreenivasa","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar","family":"Goudar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manne","family":"Munikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwesha","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Devindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacasi.2021.04.007","article-title":"Epidemiological features of cardiovascular disease in Asia","volume":"1","author":"Zhao","year":"2021","journal-title":"JACC. Asia"},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0010","first-page":"101138","article-title":"The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions","volume":"49","author":"Goh","year":"2024","journal-title":"Lancet Reg. Health West. Pac."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2020.03.013","article-title":"Cardiovascular disease and COVID-19","volume":"14","author":"Bansal","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.694318","article-title":"Plasma sphingolipid profile associated with subclinical atherosclerosis and clinical disease markers of systemic lupus erythematosus: potential predictive value","volume":"12","author":"Hammad","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/bs.ircmb.2020.02.004","article-title":"On the role of sphingolipids in cell survival and death","volume":"351","author":"Iessi","year":"2020","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.152557_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315442","article-title":"Glycosphingolipids in diabetes, oxidative stress, and cardiovascular disease: prevention in experimental animal models","volume":"23","author":"Balram","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0035","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms23052719","article-title":"Ceramides as mediators of oxidative stress and inflammation in cardiometabolic disease","volume":"23","author":"Gaggini","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.813637","article-title":"Role of globotriaosylceramide in physiology and pathology","volume":"9","author":"Celi","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.152557_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/biom14101265","article-title":"Glycosphingolipids in cardiovascular disease: insights from molecular mechanisms and heart failure models","volume":"14","author":"Huang","year":"2024","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/toxins13030222","article-title":"Shiga toxins: an update on host factors and biomedical applications","volume":"13","author":"Liu","year":"2021","journal-title":"Toxins (Basel)"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0055","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jcmg.2020.08.035","article-title":"Left ventricular mass-to-strain ratio predicts cardiac amyloid subtype","volume":"14","author":"Geenty","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152557_bb0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.152557_bb0065","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.3390\/ijms25116024","article-title":"Inflammatory and cardiovascular biomarkers to monitor Fabry disease progression","volume":"25","author":"Alonso-N\u00fa\u00f1ez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.152557_bb0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/genes15081101","article-title":"Relationship between capillaroscopic architectural patterns and different variant subgroups in Fabry disease: analysis of cases from a multidisciplinary center","volume":"15","author":"Faro","year":"2024","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-021-01466-0","article-title":"Sphingolipid lysosomal storage diseases: from bench to bedside","volume":"20","author":"Abed Rabbo","year":"2021","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0080","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.152557_bb0085","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.152557_bb0090","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/glycob\/cwab046","article-title":"Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease","volume":"31","author":"Reza","year":"2021","journal-title":"Glycobiology"},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.152557_bb0095","article-title":"Chemoenzymatic synthesis of Globo-series glycosphingolipids and evaluation of their immunosuppressive activities","volume":"17","author":"Pei-Yun","year":"2022","journal-title":"Chem. Asian J."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.152557_bb0100","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel Gb3 isoforms detected in urine of Fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152557_bb0105","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb3-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.aca.2018.02.022","article-title":"Analysis of globotriaosylceramide (Gb3) isoforms\/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography\/tandem mass spectrometry","volume":"1015","author":"Toupin","year":"2018","journal-title":"Anal. Chim. Acta"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.152557_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9102157","article-title":"The Shiga toxin receptor globotriaosylceramide as therapeutic target in Shiga toxin E. Coli mediated HUS","volume":"9","author":"Feitz","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.704685","article-title":"Structural diversities of lectins binding to the glycosphingolipid Gb3","volume":"8","author":"Siukstaite","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.152557_bb0125","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/toxins13100690","article-title":"Shiga toxins as antitumor tools","volume":"13","author":"Robert","year":"2021","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2020.12.051","article-title":"Galabiosylceramide is present in human cerebrospinal fluid","volume":"536","author":"Akiyama","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23961-9","article-title":"Ceramide structure dictates glycosphingolipid nanodomain assembly and function","volume":"12","author":"Arumugam","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/genes15010037","article-title":"Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations","volume":"15","author":"Izhar","year":"2024","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0145","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1021\/acs.jctc.0c01145","article-title":"Multiscale molecular dynamics studies reveal different modes of receptor clustering by Gb3-binding lectins","volume":"17","author":"Kociurzynski","year":"2021","journal-title":"J. Chem. Theory Comput."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.152557_bb0150","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1074\/jbc.RA120.012665","article-title":"Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease","volume":"295","author":"Ishii","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152557_bb0155","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0160","series-title":"Cardiac Manifestations in Fabry Disease","first-page":"315","author":"Murillo","year":"2023"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0165","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/biomedicines10040732","article-title":"Gb3\/cd77 is a predictive marker and promising therapeutic target for head and neck cancer","volume":"10","author":"Garc\u00eda-Hevia","year":"2022","journal-title":"Biomedicines"},{"issue":"25","key":"10.1016\/j.ijbiomac.2026.152557_bb0170","doi-asserted-by":"crossref","first-page":"24072","DOI":"10.1074\/jbc.M502244200","article-title":"Spatial and functional heterogeneity of sphingolipid-rich membrane domains","volume":"280","author":"Kiyokawa","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.152557_bb0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.152557_bb0180","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.3390\/ijms22137052","article-title":"Dietary sphingolipids contribute to health via intestinal maintenance","volume":"22","author":"Yamashita","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.plipres.2008.04.003","article-title":"Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development","volume":"48","author":"Duan","year":"2009","journal-title":"Prog. Lipid Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152557_bb0190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/mnfr.200900608","article-title":"A review on the beneficial aspects of food processing","volume":"54","author":"van Boekel","year":"2010","journal-title":"Mol. Nutr. Food Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152557_bb0195","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/nu16071061","article-title":"Diet and physical activity in Fabry disease: a narrative review","volume":"16","author":"Muscogiuri","year":"2024","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152557_bb0200","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/nu17071194","article-title":"Unraveling the hidden burden of gastrointestinal and nutritional challenges in children with Fabry disease: a systematic review with meta-analysis","volume":"17","author":"Dargenio","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2019.110664","article-title":"Could nutritional therapy take us further in our approaches to Fabry disease?","volume":"72","author":"Francini-Pesenti","year":"2020","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0210","doi-asserted-by":"crossref","first-page":"830S","DOI":"10.1093\/jn\/127.5.830S","article-title":"Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets","volume":"127","author":"Merrill","year":"1997","journal-title":"J. Nutr."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0215","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","article-title":"Inflammation and lipid signaling in the etiology of insulin resistance","volume":"15","author":"Glass","year":"2012","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152557_bb0220","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bbalip.2013.06.001","article-title":"New insights on glucosylated lipids: metabolism and functions","volume":"1831","author":"Ishibashi","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.152557_bb0230","first-page":"377","article-title":"Metabolic signaling functions of ceramides and sphingolipids","volume":"27","author":"Summers","year":"2019","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0235","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: presence and consequences","volume":"64","author":"Eijk","year":"2020","journal-title":"Essays Biochem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48426-4","article-title":"Lyso-Gb3 modulates the gut microbiota and decreases butyrate production","volume":"9","author":"Aguilera-Correa","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/glycob\/cwu187","article-title":"Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids","volume":"25","author":"Alam","year":"2005","journal-title":"Glycobiology"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.152557_bb0250","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2468-2667(18)30139-7","article-title":"Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study","volume":"3","author":"Nyberg","year":"2018","journal-title":"Lancet Public Health"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0255","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/jn\/124.5.702","article-title":"Uptake and metabolism of sphingolipids in isolated intestinal loops of mice","volume":"124","author":"Schmelz","year":"1994","journal-title":"J. Nutr."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0260","doi-asserted-by":"crossref","DOI":"10.1097\/00062752-200301000-00004","article-title":"Structure, organization, and function of glycosphingolipids in membrane","volume":"10","author":"Hakomori","year":"2003","journal-title":"Curr. Opin. Hematol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0265","doi-asserted-by":"crossref","first-page":"90","DOI":"10.46439\/signaling.1.019","article-title":"Pathogenic contribute of unaffected cardiac cells in female Fabry cardiomyopathy","volume":"1","author":"Frustaci","year":"2023","journal-title":"Cell. Signal."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.152557_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810088","article-title":"Pathogenesis and molecular mechanisms of Anderson\u2013Fabry disease and possible new molecular addressed therapeutic strategies","volume":"22","author":"Tuttolomondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152557_bb0275","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s10072-019-03754-1","article-title":"Maternal germline mosaicism in Fabry disease","volume":"40","author":"Pianese","year":"2019","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.152557_bb0280","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.152557_bb0285","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","article-title":"Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression","volume":"135","author":"Van der Veen","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.152557_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115853","article-title":"Interaction of Fabry disease and diabetes mellitus: suboptimal recruitment of kidney protective factors","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.152557_bb0295","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1034\/j.1600-0854.2003.00119.x","article-title":"Insulin signaling in microdomains of the plasma membrane","volume":"4","author":"Saltiel","year":"2003","journal-title":"Traffic"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endocr\/bqaa017","article-title":"Mitochondrial dysfunction, insulin resistance, and potential genetic implications","volume":"161","author":"Sangwung","year":"2020","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.152557_bb0305","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.3390\/molecules26113299","article-title":"The cellular and chemical biology of endocytic trafficking and intracellular delivery\u2014the GL\u2013Lect hypothesis","volume":"26","author":"Johannes","year":"2021","journal-title":"Molecules"},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.152557_bb0310","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.3390\/ijms25158273","article-title":"Inflammation, oxidative stress, and endothelial dysfunction in the pathogenesis of vascular damage: unraveling novel cardiovascular risk factors in Fabry disease","volume":"25","author":"Faro","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0315","series-title":"Neurocutaneous disorders: a clinical, Diagnostic and Therapeutic Approach","first-page":"459","article-title":"Fabry disease","author":"Germain","year":"2022"},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1420067","article-title":"Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications","volume":"11","author":"Kurdi","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1274595","article-title":"Cardiovascular disease and depression: a narrative review","volume":"10","author":"Li","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.152557_bb0330","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1111\/bph.15642","article-title":"Sphingolipid metabolism during toll-like receptor 4 (TLR4)-mediated macrophage activation","volume":"178","author":"Olona","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0335","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/biomedicines13030624","article-title":"Fabry disease: insights into pathophysiology and novel therapeutic strategies","volume":"13","author":"Thompson","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0340","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012234","article-title":"Pathological analysis of T1 pseudonormalization in the advanced stage of female Fabry cardiomyopathy","author":"Aida","year":"2025","journal-title":"Circ. Heart Fail."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.152557_bb0345","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100299","article-title":"Human Gb3\/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry","volume":"296","author":"Szymczak-Kulus","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0355","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbrc.2022.05.085","article-title":"One of the two N-glycans on the human Gb3\/CD77 synthase is essential for its activity and allosterically regulates its function","volume":"617","author":"Mikolajczyk","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0360","article-title":"Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy","volume":"24","author":"Hongo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0365","article-title":"Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla\u2212\/\u2212 zebrafish model of Fabry disease","volume":"21","author":"Osman","year":"2023","journal-title":"J. Transl. Med."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.152557_bb0370","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/hmg\/ddad073","article-title":"Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease","volume":"32","author":"Nikolaenko","year":"2023","journal-title":"Hum. Mol. Genet."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.152557_bb0375","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.3390\/ijms21186881","article-title":"Metabolism of glycosphingolipids and their role in the pathophysiology of lysosomal storage disorders","volume":"21","author":"Ryckman","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"52","key":"10.1016\/j.ijbiomac.2026.152557_bb0380","doi-asserted-by":"crossref","first-page":"22564","DOI":"10.1073\/pnas.1007290108","article-title":"Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation","volume":"107","author":"Liang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152557_bb0385","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201797674","article-title":"Glycosphingolipid metabolic reprogramming drives neural differentiation","volume":"37","author":"Russo","year":"2018","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152557_bb0390","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10157-021-02058-z","article-title":"Pathology and pathogenic pathways in fabry nephropathy","volume":"25","author":"Feriozzi","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"issue":"6684","key":"10.1016\/j.ijbiomac.2026.152557_bb0395","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg0564","article-title":"The lipid globotriaosylceramide promotes germinal center B cell responses and antiviral immunity","volume":"383","author":"Sharma","year":"2024","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0400","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41590-024-01809-w","article-title":"Facilitating broad antibody responses","volume":"25","author":"Dempsey","year":"2024","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0405","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1590\/2175-8239-jbn-3910","article-title":"CD77 levels over enzyme replacement treatment in Fabry disease family (V269M)","volume":"40","author":"Pereira","year":"2018","journal-title":"Braz. J. Nephrol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0410","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/jcm12052063","article-title":"Biochemical mechanisms beyond glycosphingolipid accumulation in Fabry disease: might they provide additional therapeutic treatments","volume":"12","author":"Bertoldi","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0415","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with \u03b1-galactosidase a","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0420","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000322558","article-title":"Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients","volume":"31","author":"Fellgiebel","year":"2011","journal-title":"Cerebrovasc. Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.152557_bb0425","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0430","first-page":"1","article-title":"Necrosis-like cell death modes in heart failure: the influence of aetiology and the effects of RIP3 inhibition","author":"Jarabicov\u00e1","year":"2025","journal-title":"Basic Res. Cardiol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0435","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4196\/kjpp.2023.27.3.231","article-title":"Lyso-globotriaosylsphingosine induces endothelial dysfunction via autophagy-dependent regulation of necroptosis","volume":"27","author":"Hwang","year":"2023","journal-title":"Korean J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0440","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000394","article-title":"Risk of death in heart disease is associated with elevated urinary globotriaosylceramide","volume":"3","author":"Schiffmann","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0445","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41436-018-0010-z","article-title":"Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients","volume":"21","author":"Hsu","year":"2019","journal-title":"Genet. Med."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.152557_bb0450","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.3390\/jcm10194422","article-title":"Atherosclerosis in Fabry disease\u2014a contemporary review","volume":"10","author":"Roy","year":"2021","journal-title":"J. Clin. Med."},{"issue":"Supplement_1","key":"10.1016\/j.ijbiomac.2026.152557_bb0455","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jeab289.274","article-title":"The presence and extent of coronary microvascular dysfunction is associated to the severity of cardiomyopathy in patients with Fabry disease","volume":"23","author":"Graziani","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152557_bb0460","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.3390\/ijms22094434","article-title":"Fabry disease and the heart: a comprehensive review","volume":"22","author":"Azevedo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0465","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1194\/jlr.M900002-JLR200","article-title":"Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide","volume":"51","author":"Baranowski","year":"2010","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152557_bb0470","doi-asserted-by":"crossref","first-page":"196","DOI":"10.31083\/j.rcm2306196","article-title":"The heart in Fabry disease: mechanisms beyond storage and forthcoming therapies","volume":"23","author":"Pieroni","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152557_bb0475","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ijms22031331","article-title":"The cardiovascular phenotype in Fabry disease: new findings in the research field","volume":"22","author":"Sorriento","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.152557_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114402","article-title":"Lysosomal functions and dysfunctions: molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease","volume":"187","author":"Horowitz","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.152557_bb0485","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11897-024-00645-1","article-title":"Fabry disease: cardiac implications and molecular mechanisms","volume":"21","author":"Weissman","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0490","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s12350-023-03261-z","article-title":"Impairment of sympathetic activity in Fabry disease cardiomyopathy: a further challenge for cardiac imaging","volume":"30","author":"Spinelli","year":"2023","journal-title":"J. Nucl. Cardiol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152557_bb0495","doi-asserted-by":"crossref","first-page":"192","DOI":"10.31083\/j.rcm2306192","article-title":"Fabry disease cardiomyopathy: a review of the role of cardiac imaging from diagnosis to treatment","volume":"23","author":"Kenneally","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.152557_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081664","article-title":"Biomarkers in Fabry disease. Implications for clinical diagnosis and follow-up","volume":"10","author":"Carnicer-C\u00e1ceres","year":"2021","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.152557_bb0505","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jmedgenet-2020-107162","article-title":"Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort","volume":"58","author":"Effraimidis","year":"2021","journal-title":"J. Med. Genet."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152557_bb0510","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jfma.2023.10.004","article-title":"Deciphering the diagnostic dilemma: a comprehensive review of the Taiwanese cardiac variant in Fabry disease","volume":"123","author":"Hwu","year":"2024","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0515","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/ijms.66448","article-title":"Fabry disease and the effectiveness of enzyme replacement therapy (ERT) in left ventricular hypertrophy (LVH) improvement: a review and meta-analysis","volume":"19","author":"Lee","year":"2022","journal-title":"Int. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152557_bb0520","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152557_bb0525","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152557_bb0530","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.152557_bb0535","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0540","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ejhf.62","article-title":"Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the working group on myocardial function of the European Society of Cardiology","volume":"16","author":"Tarone","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.152557_bb0545","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/01.RES.0000252342.61447.a2","article-title":"Heart failure and protein quality control","volume":"99","author":"Wang","year":"2006","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.152557_bb0550","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1248\/bpb.34.1653","article-title":"Molecular mechanisms of \u03b1-crystallinopathy and its therapeutic strategy","volume":"34","author":"Sanbe","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152557_bb0555","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"van der Veen","year":"2020","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026024840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026024840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:51:26Z","timestamp":1780519886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026024840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":111,"alternative-id":["S0141813026024840"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.152557","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Globotriaosylceramide (Gb3) implications in cardiovascular disease for its mechanistic insights, food chemistry aspects and clinical significance \u2014 A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.152557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152557"}}